Medical Device | October 19, 2021
Alcon announces launch of AcrySof IQ Vivity in India,
It is the first presbyopia-correcting lens implant for cataract surgery
It is the first presbyopia-correcting lens implant for cataract surgery
It recommends using the vaccine to prevent the spread of the disease
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
Remote screening of diabetic retinopathy can help in early detection, even before there are any noticeable vision changes
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
The company is expecting tremendous growth and a better quarterly performance
Subscribe To Our Newsletter & Stay Updated
